A Success Story at a Glance
CEVEC´s roots lie within the biotech cluster of Cologne. Based on a strong network of researchers and clinicians, the small biotech company was founded by an internationally renowned group of University Professors in 2003.
In 2004, only one year after CEVEC´s formation, the company accomplished its major breakthrough with the invention of the CAP Technology. Originating from immortalized primary human amniocytes, the new expression system proved to be an outstanding manufacturing platform for difficult-to-express and complex proteins.
Three years later, the entire regulatory data sets, including a cGMP master cell bank and further testings required by the authorities were completed. This important step was accompanied by the development of a transient version of the amniocyte derived expression system, the CAP-T Technology.
In late 2007, the CAP cells finally entered the market in Europe, convincing shortly afterwards also customers in the US to work with human cells for the production of complex proteins. Currently, the cells are being further optimized and fine-tuned in terms of large scale transient expression, media development, feeding strategies and vaccine production.
The CAP Technology produces highest quality proteins with human like glycosylation and sialylation patterns while outperforming the expression levels of competing standard cell lines like HEK-293T.
In 2009, CEVEC extended its US presence and successfully entered the Asia/Pacific market. Here, both cGMP and non-cGMP partners offer protein production services for third-party customers using our CAP and CAP-T expression systems.
Further aiming at commercially attractive markets, CEVEC currently also develops an early-stage pipeline of therapeutically relevant proteins that were difficult to express in the pre CAP era.